Handelsavisen
prelaunch
Companies Healthcare 2251.HK
22
2251.HK HKEX Advanced Medical Equipment & Technology

Beijing Airdoc Technology Co Ltd

HK$10,90
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,1B HKD
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Beijing Airdoc Technology Co Ltd develops and provides advanced medical equipment and technology solutions, primarily focused on healthcare diagnostics and imaging systems.

Business. Beijing Airdoc Technology Co Ltd (2251.HK) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the healthcare services and equipment sector, focusing on healthcare equipment solutions. Headquartered in Beijing, the company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2251.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2251.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Beijing Airdoc Technology Co Ltd (2251.HK) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the healthcare services and equipment sector, focusing on healthcare equipment solutions. Headquartered in Beijing, the company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    Beijing Airdoc Technology Co Ltd has a market capitalization of CNY 1,069,799,608.11, with a market price of CNY 10.47 per share. The company has 102,177,613 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance.

    The company's profitability and return metrics are not available in the current dataset, which limits the ability to compare its performance against industry benchmarks. However, the absence of disclosed balance-sheet inputs and lack of going-concern language in source documents suggest that the company may not be currently under significant financial distress.

    The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the diversification of its revenue streams or the extent of its international operations.

    The company's growth trajectory is not quantified in the current dataset. No numeric deltas or revenue history are available to determine whether the company is expanding or contracting in the current or next fiscal year.

    The risk assessment indicates that liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The dilution risk is currently low, and no adjustments have been applied to the valuation metrics.

    No recent events, such as filings or transcripts, are available in the current dataset to provide insight into the company's recent operational or strategic developments.

    Key takeaways
    • The company has a market capitalization of CNY 1,069,799,608.11 with no immediate dilution pressure.
    • No profitability or return metrics are available for comparison against industry benchmarks.
    • Revenue concentration and geographic exposure are not disclosed in the available data.
    • Growth trajectory and revenue history are not quantified in the current dataset.
    • Liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-03-27
    FY 2024 · Full-year highlights

    Revenue ¥156.4M, −23,3% YoY; Operating income −84,5% YoY.

    Revenue¥156.4M−23,3 % YoY
    Operating income-¥268.2M−84,5 % YoY
    Net income-¥255.5M−92,8 % YoY
    Free cash flow-¥240.4M−86,2 % YoY
    EPS
    Operating cash flow-¥165.4M−807,8 % YoY
    Financials
    Income statement
    Revenue¥156.4M
    Gross profit¥80.9M
    Operating income-¥268.2M
    Net income-¥255.5M
    Margins
    Gross margin51.7%
    Operating margin-171.5%
    Net margin-163.4%
    FCF margin-153.7%
    Balance sheet
    Total assets¥1.41B
    Total liabilities¥142.7M
    Total equity¥1.27B
    Cash & equivalents¥683.2M
    Long-term debt¥31.9M
    Cash flow
    Operating cash flow-¥165.4M
    CapEx-¥2.1M
    Free cash flow-¥240.4M
    SBC
    P&L flow · revenue → net income
    Revenue ¥156.4MOperating costs ¥424.5MNet income ¥255.5M
    Highlights
    • Revenue ¥156.4M, −23,3% YoY
    • Operating income −84,5% YoY
    • Net income −92,8% YoY
    • Free cash flow −86,2% YoY
    • Net margin -163.4%

    Valuation FY

    Market price
    HK$10,90
    Market cap
    HK$1.07B
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Beijing Airdoc Technology Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2251.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-03-27 19:19 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 156.4M · Net CNY -255.5M
    2023-03-23 20:28 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 204.0M · Net CNY -132.5M
    2022-03-17 19:58 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 113.7M · Net CNY -180.0M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage